In this study of patients with COVID-19 and hypoxemic respiratory failure managed outside the ICU, 63% were able to tolerate PP for more than 3 hours. However, oxygenation increased during PP in only 25% and was not sustained in half of those after resupination.

These results are consistent with findings from previous small studies of PP in nonintubated patients. A trial of PP may be a mechanism to select patients who will do well or it may be useful in a subset.

The study had several limitations. The sample was small, a single episode of PP was evaluated, the follow-up was short, clinical outcomes were not assessed, and causality of the observed changes cannot be inferred.

Further studies to identify optimal PP regimens and patients with COVID-19 in whom it may be beneficial are warranted.

A total of 88 patients with COVID-19 were admitted during the period. 63 patients did not meet inclusion criteria.

Read More